<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03128749</url>
  </required_header>
  <id_info>
    <org_study_id>CorporacionPT CIR2016/030</org_study_id>
    <nct_id>NCT03128749</nct_id>
  </id_info>
  <brief_title>Mindfulness-Based Cognitive Therapy: Efficacy and fMRI-based Response Predictors in a Group of OCD Patients</brief_title>
  <official_title>Mindfulness-Based Cognitive Therapy: Efficacy and fMRI-based Response Predictors in a Group of OCD Patients Non-responders to CBT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obsessive-Compulsive Disorder (OCD) patients have a response rate of 50-60% to exposure and
      response prevention (ERP) therapy and SSRI antidepressants. Mindfulness-Based Cognitive
      Therapy (MBCT) consists of training the participant to non-react to negative thoughts and
      emotions. Applying MBCT to OCD patients may help them behave with equanimity in response to
      their obsessions, and therefore acknowledge them with the same attention and intention as
      they admit any other disturbing thought without reacting to it. MBCT has demonstrated
      effectiveness in major depression, but much less attention has been given to MBCT in OCD. ERP
      and MBCT, although sharing aspects like exposure, are based on different theoretic and
      therapeutic factors. EPR is based on a direct anxiety habituation process whereas MBCT trains
      a holistic manner of becoming familiarized with distressful thoughts and emotions while
      learning to develop a new relationship to them. Thus, MBCT may decrease anxiety indirectly
      through a major attention awareness and non-reactivity to thoughts and emotions.

      OCD is characterized by altered cortical-striatal-thalamic-cortical (CSTC) circuit and
      default mode network (DMN) connectivity when performing different tasks and during the
      resting state. It has been establish that the ventral CSTC circuit is mostly associated with
      emotional processing, while the dorsolateral aspect of the CSTC circuit is preferentially
      involved in cognitive processing. In this regard, we hypothesized that clinical amelioration
      will be accompanied by a re-establishment of functional connectivity within dorsolateral and
      DMN circuits, which will in turn be associated with improvement of certain neuropsychological
      processes. CSTC and DMN circuits have also shown to be sensitive to prolonged stress
      situations. Specifically, childhood trauma has been related to larger brain volumes and it
      has been associated with different OCD clinical subtypes.

      Aims: 1. To assess MBCT effectiveness in treatment non-naive OCD patients. 2. To study
      cognitive and neuropsychological characteristics that mediate or moderate MBCT response. 3.
      To examine the changes in cognitive, neuropsychological and neuroimaging patterns associated
      with an MBCT intervention. 4. To identify a brain biomarker for positive response to MBCT in
      non-naïve OCD patients. 5. To study cognitive, neuropsychological and early stress expousure
      mediators or moderators of functional changes in CSTC and DMN patterns in response to MBCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Y-BOCS:</measure>
    <time_frame>Baseline and at 14 weeks and at 6 months post-treatment</time_frame>
    <description>• Clinical version of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) the severity and the checklist.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in OCI-R:</measure>
    <time_frame>Baseline, at 14 weeks and at 6 months post-treatment</time_frame>
    <description>• Obsessive-Compulsive Inventory-Revised (OCI-R) assessing 6 dimensions (Washing, Checking, Ordering, Obsessing, Hoarding and Neutralizing).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in OBQ-44:</measure>
    <time_frame>Baseline and at 14 weeks</time_frame>
    <description>• Obsessive Beliefs Questionnaire-44 (OBQ-44), a measure of three OCD-related belief domains (Perfectionism/Certainty, Importance/Control of thoughts, and Responsibility/Threat estimation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in functional brain circuits:</measure>
    <time_frame>Baseline and at 14 weeks</time_frame>
    <description>• Functional Magnetic Resonance Imaging: Resting state and during task performance (Autobiographical memory + N-Back) and self-reference.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety:</measure>
    <time_frame>Baseline and at 14 weeks</time_frame>
    <description>• Anxiety Sensitivity Index (ASI-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mood from baseline:</measure>
    <time_frame>Baseline, at 14 weeks and at 6 months post-treatment</time_frame>
    <description>• The Beck Depression Inventory (BDI-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in positive and negative affect:</measure>
    <time_frame>Baseline and at 14 weeks</time_frame>
    <description>• Positive and Negative Affect trait (PANAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of current life events:</measure>
    <time_frame>Baseline, 14 weeks and at 6 months post-treatment</time_frame>
    <description>• Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of past stressful life events:</measure>
    <time_frame>Baseline</time_frame>
    <description>• Childhood Trauma Questionnaire (CTQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in attentional domains:</measure>
    <time_frame>Baseline and at 14 weeks</time_frame>
    <description>• Conners' Continuous Performance Test II : CPT-II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in executive Functioning/Cognitive flexibility:</measure>
    <time_frame>Baseline and at 14 weeks</time_frame>
    <description>• Wisconsin Card Sorting Test: WCST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autobiographical memories:</measure>
    <time_frame>Baseline</time_frame>
    <description>• Autobiographic Memory Task: 10 selected emotions (5 negative and 5 positive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in verbal fluency:</measure>
    <time_frame>Baseline, 14 weeks and at 6 months post-treatment</time_frame>
    <description>• Phonetic Fluency: PMR (Spanish version of the FAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech analysis:</measure>
    <time_frame>Baseline</time_frame>
    <description>• Word Task: Assessment of language fluency and thought content using a list of 10 seed words from the Spanish adaptation of the ANEW (Affective Norms for English Words) in terms of positive and negative valance and different degrees of arousal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thought content:</measure>
    <time_frame>Baseline, each week during the treatment period (10 sessions) and post-treatment</time_frame>
    <description>• ES-Questionnaire, designed by Drs. J. Andrews-Hanna and M. López-Solà (research collaborators of the project) from the USA. It is based on 23 questions that examines the thought content from the patient before, during and after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life:</measure>
    <time_frame>Baseline, 14 weeks and at 6 months post-treatment</time_frame>
    <description>• Multicultural Quality of Life Index (MQLI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mindfulness variables:</measure>
    <time_frame>Baseline, 14 weeks and at 6 months post-treatment</time_frame>
    <description>• Mindfulness measures include: The Five Facet Mindfulness Questionnaire (FFMQ), used to measure the five constructs central to mindfulness (Observing, Describing, Acting with Awareness, Non-judgment of Inner Experience, and Non-reactivity to Inner Experience).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rumination:</measure>
    <time_frame>Baseline, 14 weeks and at 6 months post-treatment</time_frame>
    <description>• Ruminative Responses Scale (RRS) to measure the degree and type of thought thinking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment expectancy:</measure>
    <time_frame>Baseline</time_frame>
    <description>• Credibility Expectancy Questionnaire (CEQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in structural brain regions:</measure>
    <time_frame>Baseline and at 14 weeks</time_frame>
    <description>• Structural acquisition: T13D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Mindfulness Based Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mindfulness-based cognitive therapy (MBCT), adjusted to OCD patients, will be applied in 10 weekly sessions of 2 hours followed by an extra session 4 weeks later. The treatment will be applied in a group format of 10 to 12 patients.
These patients will be also attending to their regular psychiatric visits for medication control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual (TAU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be attending to their regular psychiatric visits during the whole trial period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindfulness Based Intervention</intervention_name>
    <description>The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams &amp; Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual &quot;The Mindfulness Workbook for OCD&quot; (Hershfield and Corboy, 2013).</description>
    <arm_group_label>Mindfulness Based Intervention</arm_group_label>
    <other_name>MBCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment as Usual</intervention_name>
    <description>The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.</description>
    <arm_group_label>Mindfulness Based Intervention</arm_group_label>
    <arm_group_label>Treatment as Usual (TAU)</arm_group_label>
    <other_name>TAU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age frame: 18-50 years old.

          -  Principal Diagnosis: Obsessive compulsive disorder.

          -  Severity of OCD symptoms: between mild (Y-BOCS=9) and severe (Y-BOCS=32)

          -  Previous structured CBT or EPR, either in group or individual format, between 10 to 20
             sessions.

          -  A maximum of three different pharmacological strategies.

          -  Minimum of IQ 85 measured by Vocabulary subtest (WAIS-IV).

          -  Minimum level of schooling: 14 years.

          -  To sign the informant consent.

        Exclusion Criteria:

          -  Organic pathology and/or neurological disorders such as brain injury or epilepsy.

          -  Comorbidity with: Mental Retardation, previous or current substance abuse, psychotic
             disorders, bipolar disorder. Other affective and/or anxiety disorders will not be an
             exclusion criteria if OCD is considered the primary diagnosis.

          -  Recent suicide attempt/active suicidality

          -  Previous completion of an MBCT course (≥ 8 weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara López-Solà, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporació Parc Taulí</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Serra-Blasco, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Parc Taulí</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pino Alonso, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bellvitge University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina López-Solà, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Andrews-Hanna, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara López-Solà, PhD</last_name>
    <phone>0034 93 723 10 10</phone>
    <phone_ext>22152</phone_ext>
    <email>clopezs@tauli.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Serra-Blasco, PhD</last_name>
    <phone>0034 93 723 10 10</phone>
    <phone_ext>22068</phone_ext>
    <email>mserrab@tauli.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Corporacion Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Lopez-Solà, PhD</last_name>
      <phone>600458159</phone>
      <email>clopezs@tauli.cat</email>
    </contact>
    <contact_backup>
      <last_name>Maria Serra-Blasco, PhD</last_name>
      <email>mariaserrblasco@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wickramaratne PJ, et al. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry. 1994 Mar;55 Suppl:5-10.</citation>
    <PMID>8077177</PMID>
  </reference>
  <reference>
    <citation>Murray CJ, Lopez AD. Evidence-based health policy--lessons from the Global Burden of Disease Study. Science. 1996 Nov 1;274(5288):740-3.</citation>
    <PMID>8966556</PMID>
  </reference>
  <reference>
    <citation>López-Solà C, Fontenelle LF, Verhulst B, Neale MC, Menchón JM, Alonso P, Harrison BJ. DISTINCT ETIOLOGICAL INFLUENCES ON OBSESSIVE-COMPULSIVE SYMPTOM DIMENSIONS: A MULTIVARIATE TWIN STUDY. Depress Anxiety. 2016 Mar;33(3):179-91. doi: 10.1002/da.22455. Epub 2015 Dec 2.</citation>
    <PMID>26630089</PMID>
  </reference>
  <reference>
    <citation>Rufer M, Fricke S, Moritz S, Kloss M, Hand I. Symptom dimensions in obsessive-compulsive disorder: prediction of cognitive-behavior therapy outcome. Acta Psychiatr Scand. 2006 May;113(5):440-6.</citation>
    <PMID>16603035</PMID>
  </reference>
  <reference>
    <citation>Mataix-Cols D, Marks IM, Greist JH, Kobak KA, Baer L. Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial. Psychother Psychosom. 2002 Sep-Oct;71(5):255-62.</citation>
    <PMID>12207105</PMID>
  </reference>
  <reference>
    <citation>Whittal ML, Robichaud M, Thordarson DS, McLean PD. Group and individual treatment of obsessive-compulsive disorder using cognitive therapy and exposure plus response prevention: a 2-year follow-up of two randomized trials. J Consult Clin Psychol. 2008 Dec;76(6):1003-14. doi: 10.1037/a0013076.</citation>
    <PMID>19045968</PMID>
  </reference>
  <reference>
    <citation>Houghton S, Saxon D, Bradburn M, Ricketts T, Hardy G. The effectiveness of routinely delivered cognitive behavioural therapy for obsessive-compulsive disorder: a benchmarking study. Br J Clin Psychol. 2010 Nov;49(Pt 4):473-89. doi: 10.1348/014466509X475414. Epub 2009 Oct 21. Review.</citation>
    <PMID>19849894</PMID>
  </reference>
  <reference>
    <citation>Jain S, Shapiro SL, Swanick S, Roesch SC, Mills PJ, Bell I, Schwartz GE. A randomized controlled trial of mindfulness meditation versus relaxation training: effects on distress, positive states of mind, rumination, and distraction. Ann Behav Med. 2007 Feb;33(1):11-21.</citation>
    <PMID>17291166</PMID>
  </reference>
  <reference>
    <citation>Benzina N, Mallet L, Burguière E, N'Diaye K, Pelissolo A. Cognitive Dysfunction in Obsessive-Compulsive Disorder. Curr Psychiatry Rep. 2016 Sep;18(9):80. doi: 10.1007/s11920-016-0720-3. Review.</citation>
    <PMID>27423459</PMID>
  </reference>
  <reference>
    <citation>Chiesa A, Anselmi R, Serretti A. Psychological mechanisms of mindfulness-based interventions: what do we know? Holist Nurs Pract. 2014 Mar-Apr;28(2):124-48. doi: 10.1097/HNP.0000000000000017. Review.</citation>
    <PMID>24503749</PMID>
  </reference>
  <reference>
    <citation>Radua J, Mataix-Cols D. Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. Br J Psychiatry. 2009 Nov;195(5):393-402. doi: 10.1192/bjp.bp.108.055046. Review.</citation>
    <PMID>19880927</PMID>
  </reference>
  <reference>
    <citation>Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev. 2008;32(3):525-49. Epub 2007 Oct 17. Review.</citation>
    <PMID>18061263</PMID>
  </reference>
  <reference>
    <citation>Beucke JC, Sepulcre J, Eldaief MC, Sebold M, Kathmann N, Kaufmann C. Default mode network subsystem alterations in obsessive-compulsive disorder. Br J Psychiatry. 2014 Nov;205(5):376-82. doi: 10.1192/bjp.bp.113.137380. Epub 2014 Sep 25.</citation>
    <PMID>25257066</PMID>
  </reference>
  <reference>
    <citation>Göttlich M, Krämer UM, Kordon A, Hohagen F, Zurowski B. Resting-state connectivity of the amygdala predicts response to cognitive behavioral therapy in obsessive compulsive disorder. Biol Psychol. 2015 Oct;111:100-9. doi: 10.1016/j.biopsycho.2015.09.004. Epub 2015 Sep 18.</citation>
    <PMID>26388257</PMID>
  </reference>
  <reference>
    <citation>Segal ZV, Williams JMG, Teasdale JD (2002) Mindfulness-based cognitive therapy for depression: a new approach to preventing relapse. Guilford, New York.</citation>
  </reference>
  <reference>
    <citation>Brooks SJ, Naidoo V, Roos A, Fouché JP, Lochner C, Stein DJ. Early-life adversity and orbitofrontal and cerebellar volumes in adults with obsessive-compulsive disorder: voxel-based morphometry study. Br J Psychiatry. 2016 Jan;208(1):34-41. doi: 10.1192/bjp.bp.114.162610. Epub 2015 Sep 3.</citation>
    <PMID>26338992</PMID>
  </reference>
  <reference>
    <citation>Lochner C, du Toit PL, Zungu-Dirwayi N, Marais A, van Kradenburg J, Seedat S, Niehaus DJ, Stein DJ. Childhood trauma in obsessive-compulsive disorder, trichotillomania, and controls. Depress Anxiety. 2002;15(2):66-8.</citation>
    <PMID>11891995</PMID>
  </reference>
  <reference>
    <citation>Goldberg X, Soriano-Mas C, Alonso P, Segalàs C, Real E, López-Solà C, Subirà M, Via E, Jiménez-Murcia S, Menchón JM, Cardoner N. Predictive value of familiality, stressful life events and gender on the course of obsessive-compulsive disorder. J Affect Disord. 2015 Oct 1;185:129-34. doi: 10.1016/j.jad.2015.06.047. Epub 2015 Jul 2.</citation>
    <PMID>26172984</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Clara López-Solà</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Obsessive-Compulsive Disorder</keyword>
  <keyword>Mindfulness Based Intervention</keyword>
  <keyword>Cognitive-Behavioral Therapy</keyword>
  <keyword>Functional Magnetic Resonance Imaging</keyword>
  <keyword>Neuropsychology</keyword>
  <keyword>Childhood Maltreatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

